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Abstract
 
We have developed a transgenic animal model to investi-
gate the effects of overexpression of rat prorenin on the car-
diovascular system. Two transgenic rat lines were generated
in which rat prorenin expression was directed to the liver by
 
a human 
 
a
 
1-antitrypsin promoter. Liver-specific expression
was confirmed by RNase protection assay. Plasma prorenin
concentrations in transgenic rats were increased 400-fold in
the males of both lines but were increased only two- to
threefold in the females. Thus, transgene expression exhib-
ited sexual dimorphism. Blood pressures were not signifi-
cantly higher in transgenic rats than in nontransgenic con-
trols. The ratio of heart weight to body weight was greater
in male transgenic rats than in the nontransgenic controls.
Histological analysis revealed severe renal lesions and hy-
pertrophic cardiomyocytes in transgenic males only. This
transgenic model demonstrates a likely role of prorenin in
the development of cardiac and renal pathology indepen-
dent of hypertension. These animals will facilitate studies of
the effects of blockade of the renin-angiotensin system and
other pharmacological interventions on the development
and treatment of cardiac, vascular, and renal lesions in-
duced by changes in this system in the absence of chronic
hypertension. (
 
J. Clin. Invest.
 
 1996. 98:1966–1970.) Key
words: blood pressure 
 
•
 
 renin-angiotensin system 
 
•
 
 plasma
renin concentration 
 
•
 
 left ventricular hypertrophy 
 
•
 
 neph-
roangiosclerosis
 
Introduction
 
Prorenin is the biosynthetic precursor of renin, a key regula-
tory enzyme of the renin-angiotensin system (RAS).
 
1
 
 Prorenin
was initially detected in amniotic fluid and then in the plasma,
where it can be processed into renin after cryoactivation, acid
activation, or proteolytic activation (1–3). The cleavage site is
located at the amino terminus of prorenin, and renin is re-
leased as a 43–amino acid species-specific peptide (4, 5). Juxta-
glomerular cells of rat and human kidneys constitute the main
site of prorenin synthesis and the exclusive site of its intracellu-
lar processing to active renin. Prorenin, which represents up to
90% of the total renin in human plasma, appears to originate
from sources other than kidney, since it is still present in
plasma after bilateral nephrectomy (6). In addition to serving
as a marker for renin biosynthesis, prorenin may increase
blood pressure either directly (7), reversibly by activation to
renin (8), or by contributing to local RAS activity (9, 10). Al-
ternatively, prorenin may exert a vasodilator effect (11) by
limiting the effects of renin. However, the roles of prorenin in
physiology and pathology are still unknown.
By targeting expression of the rat prorenin gene to the liver
under the control of the human 
 
a
 
1-antitrypsin (hAT) pro-
moter (12), we have generated two lines of transgenic rats
[TGR(hAT-rpR)]. Cardiovascular lesions were induced in the
presence of an excess of circulating prorenin of hepatic origin
and in the absence of high blood pressure. These observations
strongly suggest RAS and, in particular, prorenin as indepen-
dent cardiovascular risk factors.
 
Methods
 
Transgene construction, DNA preparation, and generation of the
transgenic rats.
 
RNA was extracted from Fisher rat kidney with the
standard RNAzol protocol (Biotecx Laboratories, Houston, TX).
cDNA was obtained by RT-PCR with two rat prorenin-specific prim-
ers (Fig. 1). Transgenic rats were generated by pronuclear microinjec-
tion of fertilized Fisher F344 rat eggs, which were reimplanted into
pseudopregnant foster mothers. Six foster mothers carried 31 pups to
term, three of which carried the transgene as demonstrated by PCR
and Southern blot analysis of DNA obtained from tail biopsies. Two
of these founders transmitted the transgene to their progeny, and the
transgenic lines TGR(hAT-rpR) 85-26 and 85-41 were established. In
these two lines, segregation of the transgene was consistent with a sin-
gle insertion site in the genome (confirmed by Southern analysis, data
not shown).
 
Expression of the transgene.
 
RNase protection assays used 
 
32
 
P-
labeled RNA prepared by transcription of a 676-nucleotide antisense
RNA from the plasmid pB
 
a
 
1-AT-ratRen (after EcoRI digestion)
with T7 RNA polymerase. Total mRNA was isolated from adrenal
glands, brain, heart, intestine, kidney, lung, muscle, spleen, submaxil-
lary gland, testis, and ovary by homogenization in guanidine isothio-
cyanate as described (13).
 
Characterization of phenotype.
 
Phenotype characterization was
performed on transgenic TGR(hAT-rpR) 85-26 and 85-41 rats hemi-
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renin-angiotensin system; TGR(hAT-rpR), (human 
 
a
 
1-antitrypsin-
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zygous for the rat prorenin and on age- and sex-matched negative
control littermates. The rats from each experimental and control
group were maintained under identical conditions and had free access
to normal food (CRM, SDS, Wilham, Essex, United Kingdom) and
tap water.
 
Renin measurements.
 
Rats were briefly anesthetized in 2% halo-
thane in oxygen (Acoma vaporizer F, International Market Supply,
Congleton, United Kingdom). Blood obtained by left ventricular
puncture was immediately mixed with 2.5 
 
3
 
 10
 
2
 
3
 
 mol/liter 
 
V
 
-phen-
anthroline and 0.1 mol/liter EDTA (10 ml/0.1 ml of whole blood) to
inhibit converting enzyme and angiotensinase activity and centri-
fuged at 4,000 
 
g
 
 for 10 min. Plasma was stored at 
 
2
 
70
 
8
 
C for subse-
quent assay. Prorenin and active renin were measured as described
previously (14, 15). For measurement of renal and liver renin content,
tissues were thawed, and renin was mechanically extracted. Protein in
tissue extracts was measured according to the method of Bradford (16).
 
Method for indirect blood pressure measurements.
 
Tail-cuff pleth-
ysmography (IITC Life Sciences, Diss, Norfolk, United Kingdom) was
performed as described previously (15) on rats anesthetized briefly as
described above. This method of indirect blood pressure measure-
ment was validated in a previous study by a simultaneous comparison
with direct blood pressure measurements (15).
 
Histopathology.
 
The kidney was examined histopathologically as
described previously (17). In addition, the heart was assessed for the
size and number of infarctions, hypertrophied cardiomyocytes, inter-
stitial and perivascular fibrosis, and vascular lesions as described pre-
viously (17). The liver was also examined histologically.
 
In situ hybridization.
 
In situ hybridization was performed as de-
scribed previously (18). Briefly, a 1.4-kb DNA probe of mouse sub-
maxillary gland renin was used after random primer labeling (19)
with d-CTP-
 
35
 
S (Amersham, Les Ulis, France). Control procedures
were performed to assess the specificity of the in situ hybridization la-
beling after digestion with RNase, followed by the previously de-
scribed technique.
 
Statistical analysis.
 
All data are expressed as means
 
6
 
SEM. Com-
parisons between groups were performed with one-way ANOVA.
 
Results
 
Expression of the transgene in the liver.
 
Renin mRNA was de-
tected in livers of transgenic rat lines 85-26 and 85-41 in both
sexes but was not found in livers of age-matched negative con-
trol littermates, confirming the specificity of the riboprobe.
RNase protection assays performed on RNA extracted from
liver showed a protected fragment of 360 nucleotides corre-
sponding to rat renin (Fig. 2). Phosphorimaging analysis
showed 60-fold higher hepatic transgene expression in males
than in females in each line. The specificity of the promoter
was checked with RNase protection assays of RNA from adre-
nal glands, brain, heart, intestine, kidney, lung, muscle, spleen,
submaxillary glands, testis, and ovary. As a positive control,
liver RNA from the same animal (30 
 
m
 
g of total RNA) was
loaded on the same gel as 120 
 
m
 
g of total RNA from the other
tissues. After a 3-wk exposure, no expression was detected in
tissues other than liver (data not shown).
 
Plasma prorenin, renin, and angiotensinogen measure-
ments.
 
Plasma prorenin was significantly higher in both lines
of transgenic male rats than in the nontransgenic male controls
(Table I). Plasma prorenin was also elevated in the females of
Figure 1. cDNA was obtained by RT-PCR with two rat prorenin-spe-
cific primers (synthesized by Oswell DNA Services, Edinburgh, 
United Kingdom): upstream primer 59ATATTGTCGACCAGA-
TGGGCGGGAGGAGG39 and downstream primer 59ATAATA-
AGCTTGGCCTAAAACTAGGGTC39. SalI and HindIII sites were 
added to 59 and 39 ends of rat renin cDNA by the PCR. The resulting 
amplification product was a 1.2-kb cDNA fragment. Amplification 
was performed over 30 cycles with 1 min of denaturation at 948C, 2 
min of annealing at 648C, and 3 min of extension at 728C. The first un-
translated exon and half of the intron were fused to a c-myc 39 splice 
acceptor (35) and added to pBluescript II SK (2) (Stratagene, La 
Jolla, CA) after a double digestion with EcoRI/HindIII. The a1-AT 
gene sequence was obtained from GenBank release 67, Accession 
No. K02212. The rat prorenin fragment was made cohesive at both 
ends and ligated to the previous plasmid after digestion with SalI and 
HindIII hosting the rat renin cDNA. To generate the final plasmid 
construct pBTGR(hAT-rpR), HindIII and XhoI sites were added to 
a SV40 polyA signal by PCR amplification of pRagU0.3ARXSV 
primers upstream 59CCCGGGGCTCGAGACATGAT39 and down-
stream 59CACATTTGTAAACTTTTACTTGC39 and cloned into 
the polylinker of the final construct.
Figure 2. In the RNase protection assay for the males, 10 mg of total 
RNA was analyzed from nontransgenic rats (lane 1), transgenic 
line 85-26 (lane 2, protected fragment of 360 bp), and transgenic line 
85-41 (lane 3). The gel was exposed for 12 h. For the females, 30 mg of 
total RNA was analyzed from nontransgenic rats (lane 4), transgenic 
line 85-26 (lane 5), and transgenic line 85-41 (lane 6). The gel was ex-
posed for 10 d. Yeast tRNA (10 mg), the undigested 676-bp probe, 
and M13 A track ladder were loaded in lanes 7, 8, and 9, respectively. 
Samples were dissolved in 30 ml of 80% formamide containing 40 mM 
Pipes, 400 mM NaCl, 1 mM EDTA, and 350,000 cpm of the gel-puri-
fied transcript, denatured at 958C for 5 min and incubated at 608C for 
20 h. RNase digestion was performed in 350 ml of buffer containing 
40 mg/ml RNase A (Sigma Chemical Co., St. Louis, MO), 2 mg/ml 
RNase T1 (Calbiochem-Novabiochem Corp., La Jolla, CA), 1 M 
Tris-HCl, 0.5 M EDTA, and 5 M NaCl at room temperature for 30 
min. After digestion with proteinase K for 10 min at 308C, samples 
were electrophoresed on denaturing 6% polyacrylamide gels.
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both lines but was 150-fold lower than in the males. Plasma re-
nin activity was not increased in either sex of transgenic rat
compared with nontransgenic controls. Angiotensinogen lev-
els were not significantly different in either transgenic line or
sex compared with nontransgenic rats. Kidney renin content
was significantly lower in transgenic males of both lines than in
the nontransgenic males. Conversely, liver renin content was
significantly increased in the transgenic rats compared with the
nontransgenic controls (Table II).
 
Blood pressure measurement.
 
Blood pressure was mea-
sured in males and females of both lines of transgenic rats (85-26
and 85-41) and in age- and sex-matched negative control litter-
mates from 5 to 20 wk of age, with an interval of 5 wk between
each measurement. Systolic blood pressure was significantly
greater in males than in females. However, systolic blood pres-
sure of males and females of both transgenic lines was not sig-
nificantly elevated compared with that of corresponding non-
transgenic controls (Table III).
 
Histology (Fig. 3).
 
Histological lesions were observed ex-
clusively in transgenic males of both lines. The renal lesions
were consistent with moderate to severe nephroangiosclerosis
(glomerulosclerosis, tubulointerstitial atrophy and inflamma-
tion, and arterial wall thickening). Glomerulosclerosis, ranked
from mild focal to terminal obsolescent pattern stages, was ob-
served in 26
 
6
 
6% of glomeruli in transgenic males whereas all
the glomeruli were normal in the other groups. Cardiac dam-
age was evidenced by hypertrophic cardiomyocytes and suben-
docardial and pericoronary fibrosis. Aortic wall hypertrophy
was observed only in transgenic males and was measured by
morphometric image analysis. The thickness of the aorta was
greater in transgenic males than in nontransgenic males
(0.120
 
6
 
0.004 vs. 0.104
 
6
 
0.005 mm, 
 
P
 
 
 
,
 
 0.05), no difference
was observed between transgenic and nontransgenic females
(0.095
 
6
 
0.006 and 0.099
 
6
 
0.006 mm, respectively).
 
In situ hybridization (Fig. 4).
 
The in situ hybridization la-
beling index of the juxtaglomerular apparatus was lower in
transgenic males than in nontransgenic males (1.5%
 
6
 
0.76 vs.
20%
 
6
 
5.0, 
 
P
 
 
 
,
 
 0.0001). Renin expression in the juxtaglomeru-
lar apparatus was normal in transgenic females and nontrans-
genic males and females, but was dramatically reduced in
transgenic males of both lines. Transgene expression was local-
ized only in liver cells of transgenic males and more specifically
in the hepatocytes of the centrilobular zone.
 
Discussion
 
Experimental and epidemiological data have demonstrated an
important role of the RAS in the pathogenesis of hypertension
associated with cardiovascular and renal lesions (20, 21). An-
giotensinogen (22), angiotensin I–converting enzyme (23), an-
giotensin II receptors (24), and active renin (25) are all associ-
ated with hypertension and result in vascular damage (9). The
role of prorenin remains uncertain (11, 26), although elevated
plasma prorenin concentrations have been implicated as a
cause of microangiopathy in diabetic patients (27).
To investigate the role of RAS in the pathogenesis of hy-
pertension, TGR (mRen2)27 transgenic rats were generated
by random integration of the mouse 
 
Ren 2
 
 renin gene and its
flanking sequences into the rat genome (28). These rats were
severely hypertensive and had target organ damage. Trans-
gene expression levels varied in different organs involved in
blood pressure homeostasis, including adrenals, kidneys, brain,
and blood vessel walls, and plasma prorenin was considerably
increased (28–31). To further understand the involvement of
the RAS in hypertension, we focused our attention on the con-
tribution of elevated prorenin (plasma and tissue) to blood
pressure elevation and on the role of extrarenal renin in blood
pressure regulation. Therefore, the TGR(hAT-rpR) rat was
designed to direct rat prorenin expression to the liver.
Although sexual dimorphism of prorenin levels has been
detected in some strains of rats (32), the extent of sexual di-
morphism in transgene expression in our study was unex-
pected because endogenous 
 
a
 
1-antitrypsin expression is only
severalfold higher in male rats than in females (33). Further-
more, RNase analysis showed that transgene mRNA level in
 
Table I. Plasma Prorenin, Active Renin, and Angiotensinogen 
Measurements
 
n
 
Prorenin PRA Angiotensinogen
 
Males
Nontransgenic 10 16.6
 
6
 
2.2 1.8
 
6
 
0.5 820.2
 
6
 
67.4
85-26 5 9557.4
 
6
 
1477.4* 2.3
 
6
 
0.6 778.6
 
6
 
17.5
85-41 9 8088.9
 
6
 
963.8* 3.1
 
6
 
0.6 905.1
 
6
 
37.8
Females
Nontransgenic 8 20.6
 
6
 
5.9 2.5
 
6
 
0.6 714.0
 
6
 
47.7
85-26 3 67.0
 
6
 
8.0* 1.5
 
6
 
1.1 730.0
 
6
 
70.0
85-41 9 52.0
 
6
 
23.1* 2.5
 
6
 
0.7 626.9
 
6
 
24.7
Prorenin, PRA (plasma renin activity), and angiotensinogen measured 
in ng of angiotensin I/ml/h, *
 
P
 
 
 
,
 
 0.001 vs. nontransgenic rats.
 
Table II. Renin Activity in Male Kidney and Liver
 
n
 
Kidney renin Liver renin
 
Nontransgenic 7 2.36
 
6
 
0.74 0
85-26 4 0.45
 
6
 
0.26* 0.22
 
6
 
0.04*
85-41 6 0.20
 
6
 
0.09* 0.28
 
6
 
0.17*
Kidney and liver renin measured in ng of angiotensin I/mg protein/h,
*
 
P
 
 
 
,
 
 0.001 vs. nontransgenic rats.
 
Table III. Systolic Blood Pressure and Heart Weight/Body 
Weight Ratio
 
n
 
SBP 5 SBP 10 SBP 15 SBP 20 HW/BW
 
Males
Nontransgenic 8 112
 
6
 
4 125
 
6
 
4 103
 
6
 
3 11064 0.2960.02
85-26 5 12169 11969 11768 11969 0.3560.02*
85-41 7 116610 13369 12367 12569 0.3860.02*
Females
Nontransgenic 6 11463 11566 9563 9865 0.360.02
85-26 2 10264 104610 9268 9568 0.360.02
85-41 5 10766 12369 9765 110610 0.360.02
SBP 5, 10, 15, 20 indicate systolic blood pressure (mmHg) at 5, 10, 15,
and 20 wk of age. HW/BW is heart weight to body weight ratio (3100),
*P , 0.01 vs. nontransgenic rats.
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the liver of both transgenic lines was 60-fold higher in males
than in females and that the plasma prorenin level was 150-
fold higher in the males. This sexual dimorphism provided an
internal control for the biochemical and histological character-
istics of the transgenic male rats. Prorenin expression in the
liver and hepatic and plasma prorenin levels were not in-
creased in age-matched transgenic females and nontransgenic
animals, and no histological abnormalities were observed in
these same rats. The hAT promoter used in the rat was specific
for the liver, and no other sites of expression were detected by
RNase protection assays of a large range of tissues.
These transgenic rats manifest a large increase in plasma
prorenin concentration as a result of constitutive prorenin se-
cretion by the liver. Plasma renin activity (i.e., active renin
concentration) in transgenic male rats is slightly elevated. This
result might be explained by factors that influence renin mea-
Figure 3. Histopathological analysis of kid-
ney (A, C, D) and heart (B, E) from trans-
genic male rat (top) and nontransgenic 
male control (bottom). In the nontrans-
genic control rat, no lesions were observed 
in the kidney (arrow, interlobular artery) 
(A), and cardiomyocytes were of normal 
size (B). In the transgenic male rat, glomer-
ulosclerosis (C) and a severe arterial lesion 
with fibrinoid necrosis (arrow) (D) were 
observed in the kidney, and hypertrophic 
cardiomyocytes were observed in myocar-
dium (E). All slides were stained with
Mason’s trichrome stain. G, glomerulus;
T, tubule. Original magnifications: A, C, D, 
3200; B, E, 3750.
Figure 4. In situ hybridization with a 1.2-kb 
rat renin cDNA probe labeled with 35S. Fro-
zen sections from nontransgenic male rat 
kidney (A), transgenic male kidney (B), 
transgenic male liver (C–E), and nontrans-
genic female liver (F). In the nontransgenic 
rat (A), a strong renin signal was detected in 
the juxtaglomerular apparatus (arrow); orig-
inal magnification, 3450. In transgenic male 
rats, renin expression was abolished in the 
juxtaglomerular apparatus and arterial walls 
are thickened (arrows) (B); hepatic expres-
sion of the transgene was prominent in cen-
trilobular areas (C), but the specific signal 
was abolished in the presence of RNase (D) 
(C and D, arrows, hepatic vein; dark-field 
view, 3120); and transgene expression was 
localized in the hepatocytes (arrow, hepatic 
vein, 3450) (E). In transgenic females (F), 
no transgene expression was detected in 
hepatocytes (arrow, hepatic vein, 3450).
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surements, including the method of blood sampling, the type
of anesthesia used, age- and strain-dependent effects, and the
method of renin assay. Therefore, we designed our study to
minimize potential interferences dependent on the methodol-
ogy. Plasma active renin and prorenin were measured after
several precautions had been taken (15). However, a degree of
in vitro cold activation probably occurred (i.e., the slightly in-
creased level of active renin). This was also confirmed by the
fact that the angiotensinogen concentration was not decreased.
Blood pressures were measured in nontransgenic and
transgenic rats from either sex or line from 5–20 wk of age.
The absence of hypertension in this chronic model is consis-
tent with data from monkeys in which short-term infusion of
human prorenin did not increase blood pressure or active re-
nin concentration (6). Even if a minor increase in blood pres-
sure was not detected by tail plethysmography, lesions with the
degree of severity seen in our study have only been observed
in other animal models with markedly elevated blood pressure
levels. Phenotypic changes were observed in the kidney of
male rats of both lines, including glomerulosclerosis, tubuloin-
terstitial lesions, and severe vascular lesions. These renal le-
sions were unexpected. Our observation that renal renin con-
tent and prorenin expression were decreased supports the
interpretation that local activation of prorenin generates an-
giotensin II (9, 34).
The TGR(hAT-rpR) rat demonstrates that long-term ex-
posure to elevated prorenin is vasculotoxic. Additional studies
will be required to characterize further this new transgenic
model and, in particular, to determine the cause of the sexual
dimorphism in transgene expression. This model will facilitate
the study of the effects of RAS blockade and other pharmaco-
logical interventions on the development and treatment of car-
diac, vascular, and renal lesions in the absence of chronic hy-
pertension.
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